Rilotumumab
- Product Name
- Rilotumumab
- CAS No.
- 872514-65-3
- Chemical Name
- Rilotumumab
- Synonyms
- AMG 102;Rilotumumab;Rilotumumab (anti-HGF);Research Grade Rilotumumab;Research Grade Rilotumumab(DHD03702)
- CBNumber
- CB48080800
- Formula Weight
- 0
- MOL File
- Mol file
Rilotumumab Property
- form
- Liquid
- color
- Colorless to light yellow
Rilotumumab Chemical Properties,Usage,Production
Description
Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.
Uses
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].
Clinical Use
A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.
in vivo
Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2].
| Animal Model: | 6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2] |
| Dosage: | 1.5 mg/kg |
| Administration: | Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days |
| Result: | Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001). |
References
[1] Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. DOI:10.1158/1078-0432.CCR-12-2605
[2] Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. DOI:10.1038/onc.2014.448
Rilotumumab Preparation Products And Raw materials
Raw materials
Preparation Products
Rilotumumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 021-59167510 18117107507
- vip@med-life.cn
- Country
- China
- ProdList
- 5002
- Advantage
- 58